Search
Neuphoria Therapeutics Inc
NEUPAdd to Watchlist
3.300USD
-0.010-0.30%
Close 10-16 16:00（ET）
17.82MMarket Cap
LossP/E TTM
Neuphoria Therapeutics Inc (NEUP) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Neuphoria Therapeutics Inc in the past month.
Hold
0 Strong Buy
0 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
7.000USD+80.88%
NEUP Analyst Recommendation Trends
In the current month, NEUP has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NEUP average Analyst price target in the last month is 7.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
3
3
3
NEUP Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Revolution Medicines Inc
RVMD
9
14
1
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, NEUP EPS is projected to reach -1.580 in FY2027Q1, following reported EPS of -0.907 in FY2026Q4. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
Forecast
-1.46
-0.97
-0.56
-1.58
-1.64
Actual
0.41
-0.09
-0.91
--
--
Surprise
+128.08%
+90.38%
-61.96%
--
--
FAQs
What is Neuphoria Therapeutics Inc's price target?
Analysts forecast that Neuphoria Therapeutics Inc's price target is USD 7.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 7.00.
How have Neuphoria Therapeutics IncNEUP's recent earnings per share performed?
The market expectation was USD -0.91, while Neuphoria Therapeutics IncNEUP's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD -1.58.
What is the analyst rating for Neuphoria Therapeutics Inc?
Based on the ratings of Neuphoria Therapeutics Inc's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.